drugset / Trial / NCT03177837

Effect of Acetazolamide on Exercise Performance in Patients With Respiratory Disease at Altitude

NCT03177837

RandomizedParallel-groupQuadruple-blindPrevention

Summary

In this trial, the investigators will evaluate the effect of acetazolamide (375 mg per day) vs. placebo on exercise performance at altitude in patients with COPD.

Timeline

Start
2017-05-24
Primary completion
2018-08-02
Completion
2018-08-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetazolamide Small molecule 375 mg Oral